Document:

EX 10.1 Carrizo Employee Officer Performance Share

Exhibit 10.1 
INCENTIVE PLAN 
OF 
CARRIZO OIL & GAS, INC.
PERFORMANCE SHARE AWARD AGREEMENT 
(Officer)
THIS AGREEMENT (the “Agreement”) is effective as of the _____ day of _____, 20__ (the “Grant Date”), by and between Carrizo Oil & Gas, Inc., a Texas corporation (the “Company”), and _____________ (the “Grantee”).
The Company has adopted the Incentive Plan of Carrizo Oil & Gas, Inc., as amended and restated effective April 30, 2009 (as amended, modified or supplemented from time to time, the “Plan”), by this reference made a part hereof, for the benefit of eligible employees, directors and independent contractors of the Company and its Subsidiaries.  Capitalized terms used and not otherwise defined herein shall have the meaning ascribed thereto in the Plan.
Pursuant to the Plan, the Committee, which has generally been assigned responsibility for administering the Plan, has determined that it would be in the interest of the Company and its stockholders to grant the performance shares provided herein in order to provide Grantee with the potential to earn additional remuneration for services rendered, to encourage Grantee to remain in the employ of the Company or its Subsidiaries and to increase Grantee’s personal interest in the continued success and progress of the Company.
The Company and Grantee therefore agree as follows:
1.Grant of Performance Shares.  Pursuant to the Plan and subject further to the terms and conditions herein, the Company and Grantee enter into this Agreement pursuant to which the Grantee has a target of ________ performance shares (the “Target Award”) where each performance share represents the value of one share of Common Stock or the cash equivalent thereof (“Performance Shares”).  The range of Performance Shares which may be earned by the Grantee is 0 to 200% of the Target Award.  Based on the Total Shareholder Return Performance Goal and the Production Performance Goal set forth in this Agreement (together, the “Performance Goals”), the Performance Shares will vest, if at all, and result in the right to receive cash or shares of Common Stock in accordance with the terms of this Agreement.
2.    Total Shareholder Return Performance Goal.  Subject further to the Production Performance Goal set forth in paragraph 3 below, awards of Performance Shares will be paid to the Grantee, if at all, following the close of the _____ year period beginning on the Grant Date and ending on  ____________, 20___ (the “Performance Period”) based upon the TSR (as defined below) of the Company relative to the TSR for the Peer Companies for the Performance Period (the "Total Shareholder Return Performance Goal").
“Peer Companies” means the companies listed on Schedule A. Any of the Peer Companies that cease to be publicly traded on a recognized stock exchange during the Performance Period will be removed from the Peer Companies for the Performance Period. No companies may be added to the Peer Companies for the Performance Period.

-1-

Except as otherwise provided in paragraphs 4 and 5 below, total shareholder return (“TSR”) for a company, including the Company, will be the result of the average Fair Market Value (as defined in the Plan) for the [describe number of days] prior to the end of the Performance Period, minus the Fair Market Value on the Grant Date, plus dividends (cash or stock based on ex-dividend date) paid per share of common stock during the Performance Period, divided by the Fair Market Value on the Grant Date.
Following the close of the Performance Period, the Peer Companies and the Company shall be ranked together based on their TSR for the Performance Period from the highest TSR being number 1 to the lowest TSR being the number of Peer Companies, including the Company. Based on the Company's relative TSR rank among the Peer Companies for the Performance Period, Grantee will have earned Performance Shares, subject to the Production Performance Goal set forth below, as determined by the Company's rank as follows:
		
	•
	If the Company is ranked number 1, 200% of the Target Award

		
	•
	If the Company is ranked at the 75th percentile of the Peer Companies, including the Company, 150% of the Target Award

		
	•
	If the Company is ranked at the 50th percentile or median of the Peer Companies, including the Company, 100% of the Target Award

		
	•
	If the Company is ranked at the 25th percentile of the Peer Companies, including the Company, 50% of the Target Award

		
	•
	If the Company is ranked below the 25th percentile of the Peer Companies, including the Company, 0% of the Target Award

If the Company is ranked between any of these payout levels, the percentage multiple of the Target Award will be linearly interpolated based on the actual percentile ranking of the Company in relation to the payout levels. Any partial shares will be rounded up to the next whole number.
3.    Production Performance Goal.  Subject further to the Total Shareholder Return Performance Goal set forth in paragraph 2 above, Awards of Performance Shares will be paid to the Grantee, if at all, following the close of the Performance Period, provided that the Committee has certified that [Describe Production Performance Goal] (the “Production Performance Goal”).
4.    Payment of Performance Shares.  Performance Shares earned for the Performance Period will be issued to the Grantee only following (i) the Committee's certification of the Company’s actual TSR relative to the Peer Companies actual TSR for the Performance Period pursuant to the Total Shareholder Return Performance Goal and (ii) the Committee’s certification that the Company’s Production Performance Goal was achieved.  If the Committee does not certify that the Production Performance Goal was achieved, all Performance Shares awarded under this Agreement shall be forfeited.
Notwithstanding the foregoing, subject to the provisions of paragraph 5 and the applicable written employment agreement between the Grantee and the Company or any Subsidiary, if any (the “Employment Agreement”), no Performance Shares shall be payable unless the Grantee has been in the continuous employment of the Company and its Subsidiaries through the last day of the Performance Period.  A change of employment is continuous employment within the meaning of 

-2-

this paragraph 4 provided that, after giving effect to such change, the Grantee continues to be an employee of the Company or any Subsidiary.
Performance Shares payable to a Grantee will be paid in a lump sum distribution of shares of Common Stock to the Grantee no later than thirty (30) days following the last day of the Performance Period, except that (i) in the event of a death that occurs during the first two (2) years of the Performance Period, payment will be made on the thirtieth (30th) day following the date of death and (ii) in the event of a Change in Control, payment will be made on the thirtieth (30th) day following the date of the Change in Control.  In the event this paragraph is applicable, payout of the Performance Shares will be calculated as described in paragraph 5 below.
For purposes of this paragraph 4, a lump sum distribution of shares of Common Stock to the Grantee shall mean that the Company will deliver to the Grantee one of the following, as determined in the Committee’s sole discretion: (i) certificates representing the applicable number shares of Common Stock or cause the applicable number of shares of Common Stock to be evidenced in book-entry form in the Grantee’s name in the stock register of the Company maintained by the Company’s transfer agent, (ii) cash equal to the Fair Market Value of the applicable number of shares of Common Stock, or (iii) any combination of (i) or (ii).
5.    Termination of Employment or Change in Control Prior to End of Performance Period.  Upon termination of the Grantee’s employment with the Company or any Subsidiary (or the successor of any such company) for any reason prior to the end of the Performance Period, all Performance Shares shall be immediately forfeited to the Company; subject, however, to the provisions of the Employment Agreement.  Notwithstanding the provisions of the Employment Agreement, if (a) a Change of Control has not occurred and (b) the Grantee (i) is terminated without Cause (as defined in the Employment Agreement) or (ii) resigns for Good Reason (as defined in the Employment Agreement) prior to the satisfaction of the Performance Goals, no Performance Shares will be payable unless and until the Performance Goals have been satisfied.
Notwithstanding the foregoing, in the event of the death or disability of the Grantee during the Performance Period, either of which occurs before a Change in Control, the Grantee (or estate) will receive a pro-rata payment (based on the number of completed months during the Performance Period compared to the total number of months in the Performance Period) based on actual results at the end of the Performance Period. Notwithstanding, in the event of a death that occurs during the first two (2) years of the Performance Period, such pro-rata payment will be based on actual results through the date of death with the TSR calculated based upon the average Fair Market Value for the fifteen (15) trading days ending eleven (11) calendar days prior to the date of death.
In the event of a Change in Control, if less than one-half of the Performance Period has elapsed with respect to an award of Performance Shares, then one hundred percent (100%) of the Target Award for the Performance Period will be paid to the Grantee, otherwise the greater of (i) one hundred percent (100%) of the Target Award or (ii) the percentage corresponding to the actual performance level achieved as of the date of the Change in Control, with the TSR calculated based upon the average Fair Market Value for the fifteen (15) trading days ending eleven (11) calendar days prior to the date of the Change in Control, will be paid to the Grantee.
6.    No Ownership Rights Prior to Issuance of Shares of Common Stock; Dividend Equivalents.  Neither the Grantee nor any other person shall become the beneficial owner of the 

-3-

shares of Common Stock underlying the Performance Shares, nor have any rights of a shareholder (including, without limitation, dividend and voting rights) with respect to any such shares of Common Stock, unless and until and after such shares of Common Stock have been delivered to the Grantee as described in the last subparagraph of paragraph 4.
7.    Transfer Restrictions.  Except as expressly provided herein, the Performance Shares are not transferable (voluntarily or involuntarily) other than by will or the laws of descent and distribution or pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act, or the rules thereunder (a “QDRO”), and may not otherwise be assigned, pledged, hypothecated or otherwise disposed of and shall not be subject to execution, attachment or similar process.  Upon any attempt to effect any such disposition, or upon the levy of any such process, the award provided for herein shall immediately become null and void, and the Performance Shares shall be immediately forfeited.
Notwithstanding the foregoing, the Performance Shares are transferable by the Grantee to (i) the children or grandchildren of the Grantee (“Immediate Family Members”), (ii) a trust or trusts for the exclusive benefit of such Immediate Family Members, or (iii) a partnership or partnerships in which such Immediate Family Members have at least ninety‐nine percent (99%) of the equity, profit and loss interests.  Subsequent transfers of Performance Shares shall be prohibited except by will or the laws of descent and distribution or pursuant to a QDRO, unless such transfers are made to the original Grantee or a person to whom the original Grantee could have made a transfer in the manner described herein.  No transfer shall be effective unless and until written notice of such transfer is provided to the Committee, in the form and manner prescribed by the Committee.  Following transfer, the Performance Shares shall continue to be subject to the same terms and conditions as were applicable immediately prior to transfer, and, except as otherwise provided herein, the term “Grantee” shall be deemed to refer to the transferee.  The consequences of termination of employment shall continue to be applied with respect to the original Grantee.
8.    Adjustments.  As provided in Section 15 of the Plan, certain adjustments may be made to the Performance Shares upon the occurrence of events or circumstances described in Section 15 of the Plan.
9.    Mandatory Withholding of Taxes.  Grantee acknowledges and agrees that the Company shall deduct from the shares of Common Stock or cash otherwise payable or deliverable an amount of cash and/or number of shares of Common Stock (valued at their Fair Market Value) that is equal to the amount of all federal, state and local taxes required to be withheld by the Company, as determined by the Committee.  In the event the Company, in its sole discretion, determines that the Grantee’s tax obligations will not be satisfied under the methods otherwise expressly described above, the Grantee, subject to compliance with the Company’s insider trading policies, authorizes the Company or the Company’s Stock Plan Administrator, currently UBS Financial Services Inc., to (i) sell a number of shares of Common Stock issued or outstanding pursuant to the award, which number of shares of Common Stock the Company determines has at least the market value sufficient to meet the tax withholding obligations, plus additional shares of Common Stock to account for rounding and market fluctuations and (ii) pay such tax withholding to the Company.  The shares of Common Stock may be sold as part of a block trade with other Participants such that all Participants receive an average price.

-4-

10.    Restrictions Imposed by Law.  Without limiting the generality of Section 16 of the Plan, the Grantee agrees that the Company will not be obligated to issue or deliver any shares of Common Stock if counsel to the Company determines that such delivery would violate any applicable law or any rule or regulation of any governmental authority or any rule or regulation of, or agreement of the Company with, any securities exchange or association upon which the Common Stock is listed or quoted.  The Company shall in no event be obligated to take any affirmative action in order to cause the issuance or delivery of shares of Common Stock to comply with any such law, rule, regulation or agreement.
11.    Notice.  Unless the Company notifies the Grantee in writing of a different procedure, any notice or other communication to the Company with respect to this Agreement shall be in writing and shall be (a) delivered personally to the following address:
Carrizo Oil & Gas, Inc.
500 Dallas Street, Suite 2300
Houston, Texas  77002
Attention: Human Resources
with a copy to:
Carrizo Oil & Gas, Inc.
500 Dallas Street, Suite 2300
Houston, Texas  77002
Attention: Law Department
or (b) sent by first class mail, postage prepaid and addressed as follows:
Carrizo Oil & Gas, Inc.
500 Dallas Street, Suite 2300
Houston, Texas  77002
Attention: Human Resources
with a copy to:
Carrizo Oil & Gas, Inc.
500 Dallas Street, Suite 2300
Houston, Texas  77002
Attention: Law Department
Any notice or other communication to the Grantee with respect to this Agreement shall be in writing and shall be delivered personally, or shall be sent by first class mail, postage prepaid, to Grantee’s address as listed in the records of the Company on the Grant Date, unless the Company has received written notification from the Grantee of a change of address.
12.    Amendment.  Notwithstanding any other provisions hereof, this Agreement may be supplemented or amended from time to time as approved by the Committee as contemplated by Section 6 of the Plan.  Without limiting the generality of the foregoing, without the consent of the Grantee, (a) this Agreement may be amended or supplemented (i) to cure any ambiguity or to correct 

-5-

or supplement any provision herein which may be defective or inconsistent with any other provision herein, or (ii) to add to the covenants and agreements of the Company for the benefit of Grantee or surrender any right or power reserved to or conferred upon the Company in this Agreement, subject, however, to any required approval of the Company’s stockholders and, provided, in each case, that such changes or corrections shall not adversely affect the rights of Grantee with respect to the award evidenced hereby without the Grantee’s consent, or (iii) to make such other changes as the Company, upon advice of counsel, determines are necessary or advisable because of the adoption or promulgation of, or change in or of the interpretation of, any law or governmental rule or regulation, including any applicable federal or state securities laws; and (b) subject to Section 6 of the Plan and any required approval of the Company’s stockholders, the award evidenced by this Agreement may be canceled by the Committee and a new award made in substitution therefor, provided that the award so substituted shall satisfy all of the requirements of the Plan as of the date such new award is made and no such action shall adversely affect the Performance Shares without the Grantee’s consent.
13.    Grantee Employment.  Nothing contained in this Agreement, and no action of the Company or the Committee with respect hereto, shall confer or be construed to confer on the Grantee any right to continue in the employ of the Company or any of its Subsidiaries or interfere in any way with the right of the Company or any employing Subsidiary to terminate the Grantee’s employment at any time, with or without cause; subject, however, to the provisions of the Employment Agreement.
14.    Governing Law.  This Agreement shall be governed by, and construed in accordance with, the internal laws of the State of Texas.
15.    Construction.  References in this Agreement to “this Agreement” and the words “herein,” “hereof,” “hereunder” and similar terms include all exhibits and schedules appended hereto, including the Plan.  This Agreement is entered into, and the award evidenced hereby is granted, pursuant to the Plan and shall be governed by and construed in accordance with the Plan and the administrative interpretations adopted by the Committee thereunder.  All decisions of the Committee upon questions regarding the Plan or this Agreement shall be conclusive.  Unless otherwise expressly stated herein, in the event of any inconsistency between the terms of the Plan and this Agreement, the terms of the Plan shall control.  The headings of the paragraphs of this Agreement have been included for convenience of reference only, are not to be considered a part hereof and shall in no way modify or restrict any of the terms or provisions hereof.
16.    Duplicate Originals.  The Company and the Grantee may sign any number of copies of this Agreement.  Each signed copy shall be an original, but all of them together represent the same agreement.
17.    Rules by Committee.  The rights of the Grantee and obligations of the Company hereunder shall be subject to such reasonable rules and regulations as the Committee may adopt from time to time hereafter.
18.    Entire Agreement.  Subject to the provisions of the Employment Agreement, Grantee and the Company hereby declare and represent that no promise or agreement not herein expressed has been made and that this Agreement contains the entire agreement between the parties hereto with respect to the Performance Shares and replaces and makes null and void any prior 

-6-

agreements, oral or written, between Grantee and the Company regarding the Performance Shares.  To the extent of any conflict between this Agreement and the Employment Agreement, the terms of the Employment Agreement shall control; provided, however, that the parties acknowledge and agree that to the extent set forth in the last sentence of the first subparagraph of paragraph 5, the provisions of this Agreement modify and supersede the terms of the Employment Agreement with respect to the consequences to this award of Performance Shares of a termination of employment without Cause or a resignation for Good Reason prior to a Change of Control.
19.    Section 409A.  Payments under this Agreement are designed to be made in a manner that is exempt from Section 409A of the Code as a “short-term deferral,” and the provisions of this Agreement will be administered, interpreted and construed accordingly (or disregarded to the extent such provision cannot be so administered, interpreted, or construed).
20.    Grantee Acceptance.  Grantee shall signify acceptance of the terms and conditions of this Agreement by signing in the space provided at the end hereof and returning a signed copy to the Company.
ATTEST:                        CARRIZO OIL & GAS, INC.
By:                        
Secretary                                S. P. Johnson, IV    
President 

ACCEPTED:

    
[Name]            

-7-

Schedule A to Performance Share Award Agreement dated as of _________, 20___
SCHEDULE A
PEER COMPANIES

The following companies compromise the Peer Companies for the Performance Period:

[Describe Peer Companies]

-1-Exhibit 10.8

 

May 5, 2014

 

Mr. Rick E Winningham

 

Dear Rick:

 

I am pleased to invite you to join Theravance Biopharma, Inc. (“Theravance Biopharma”) and Theravance Biopharma US, Inc. (the “Company” or “Theravance Biopharma US”) as President and Chief Executive Officer.  You will be an employee of Theravance Biopharma US shortly before the effective date of the spin-off of Theravance Biopharma from Theravance, Inc. (the “Spin-Off”).  The Company is a wholly-owned Delaware operating subsidiary of Theravance Biopharma.

 

At Theravance Biopharma US, you will serve in the exempt position of President and Chief Executive Officer, providing services on a part-time basis and reporting to the Board of Directors of Theravance Biopharma.  The Company is aware that you will continue to provide services to Theravance, Inc. as its President and Chief Executive Officer for a period of time until your successor at Theravance, Inc. is identified and retained and as a member of Theravance, Inc.’s Board of Directors.  It is agreed that you may engage in such activities so long as they do not conflict with your obligations to the Company or Theravance Biopharma.  In this regard, you agree to abide by the terms of the Theravance Biopharma Conflict of Interest Policy (including the addendum thereto with regard to Theravance, Inc. matters) at all times during your employment.

 

Your salary on an annualized basis will be $177,166 per year.  You will also be eligible to receive an annual discretionary bonus with a target amount of 60% of your base salary earned in 2014 (and each calendar year thereafter), based on the Company’s performance against its annual goals and a review of your individual performance.  Except to the limited extent provided herein, you will be required to be an active employee in good standing at the time the bonus is paid in order to receive the bonus, which will be no later than 21⁄2 months after the close of the calendar year.  If your employment with the Company terminates in connection with your resuming full-time employment with Theravance, Inc., you will remain eligible to receive a partial year bonus for the calendar year in which such employment change occurs.  Consistent with the Company’s standard bonus practices, the bonus would be determined by the Compensation Committee in its discretion based on the Company’s performance against its annual goals and a review of your individual performance and would be paid following the end of such calendar year but in any event by March 15th.  Your salary and target bonus may be changed from time-to-time at the sole discretion of the Board of Directors or its Compensation Committee.

 

 

As a part-time employee, you will be eligible to participate in all of the Company-sponsored benefits that are provided by the Company to its employees to the extent you satisfy the eligibility criteria for such plans.  Notwithstanding the foregoing, regardless of whether you satisfy the eligibility criteria for the Company’s Change in Control Severance Plan (which currently requires that you be a full-time employee), you will not be eligible to participate in the Company’s Change in Control Severance Plan while you remain President and Chief Executive Officer of Theravance, Inc.

 

In addition, subject to the approval of the Theravance Biopharma Board of Directors or its Compensation Committee, you will be granted two options to purchase Common Shares of Theravance Biopharma at a per share purchase price equal to the fair market value of one Theravance Biopharma Common Share on the date of grant, one option for 80,000 Common Shares of Theravance Biopharma (the “First Option”) and a second option for 36,000 Common Shares of Theravance Biopharma (the “Second Option” and together with the First Option, the “Options”).  The Options will be subject to the terms and conditions applicable to options granted under the Theravance Biopharma 2013 Equity Incentive Plan (the “Plan”), as described in the Plan and the applicable Stock Option Agreements.  The First Option will vest with respect to 25% of the option shares after 12 months of continuous service following the commencement of your employment with the Company, and the balance of the First Option will vest in equal monthly installments over the next 36 months of continuous service thereafter, as described in the applicable Stock Option Agreement.  The Second Option will vest with respect to 20% of the option shares after 12 months of continuous service following the commencement of your employment with the Company, and the balance of the Second Option will vest in equal monthly installments over the next 48 months of continuous service thereafter, as described in the applicable Stock Option Agreement.  Should you become a full-time employee of the Company, the terms of any additional equity awards, including options, will be negotiated at that time.

 

Your employment pursuant to this offer is contingent on you executing the Company’s standard form of Proprietary Information and Inventions Agreement.  You must also review and acknowledge receipt of the enclosed Employee Handbook.  You will be expected to abide by its terms.  In addition, we will need all employees to present documents establishing their legal right to work in the United States as required by the government’s Form I-9.  We will set up a time to meet with you to complete the necessary paperwork.

 

While we hope that your employment with Theravance Biopharma US will be mutually satisfactory, your employment status will remain at-will.  As a result, both you and the Company are free to terminate the employment relationship at any time for any reason, with or without cause.  This is the full and complete agreement between us on this term.  Although your job duties, title, compensation and benefits, as well as the Company’s personnel policies and procedures to which you will be subject, may change from time-to-time, the “at-will” nature of your employment may only be changed in an express writing signed by you and the Lead Independent Director of Theravance Biopharma.  Notwithstanding the foregoing, if your employment is terminated by the Company without cause and you incur a separation, and

 

2

 

provided you do not resume and/or return to full-time employment or service with Theravance, Inc. in connection with such separation, the Company will make a lump sum payment to you (less all applicable withholding taxes) of 24 months’ salary (at the rate in effect at the time of your separation) plus 2 times your then current target bonus, provided that as a condition to receiving such severance payment you execute the Company’s standard form of release required of all employees who receive any severance pay.  The form of release will be delivered to you within 30 days after your separation and you must execute and return the release within the time period set forth in the form of release, which will in no event be later than 50 days after your separation.  If you fail to return the release on or before the deadline set forth in the form of release, or if you revoke the release, then you will not be entitled to the severance payment.  Provided you satisfy such release requirements, the severance payment will be paid within 60 days after your separation; however, if such 60-day period spans two calendar years, then the severance payment will in any event be made in the second calendar year.

 

For purposes of the above severance provision, a termination “without cause” shall mean termination for any reason other than: (i) unauthorized use or disclosure of the confidential information or trade secrets of Theravance Biopharma (or any parent or subsidiary), which use causes material harm to Theravance Biopharma (or any parent or subsidiary), (ii) conviction of a felony under the laws of the United States or any state thereof, (iii) gross negligence, or (iv) repeated failure to perform lawful assigned duties for thirty days after receiving written notification from Theravance Biopharma’s Board of Directors.  For purposes of the above severance provision, “separation” means a “separation from service,” as defined in the regulations under Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”).

 

To the extent the severance payment described in this letter is deemed to be nonqualified deferred compensation that is subject to Section 409A of the Code and if the Company determines that you are a “specified employee” under Section 409A(a)(2)(B)(i) of the Code at the time of your separation, then the severance payment will be made on the first business day following (i) expiration of the six-month period measured from your separation or (ii) the date of your death.

 

*              *              *

 

3

 

This letter sets forth the terms of your employment with us and supersedes any prior representations or agreements, whether written or oral.  A duplicate original of this offer is enclosed for your records.  To accept this offer, please sign and return this letter to me.

 

	
 
    	
Sincerely,
    
	
 
    	
 
    
	
 
    	
Theravance   Biopharma, Inc.
    
	
 
    	
 
    
	
 
    	
/s/   William D. Young
    
	
 
    	
By:   William D. Young
    
	
 
    	
Title:   Lead Independent Director
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
I have read and accept this employment offer:
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
/s/ Rick E Winningham
    	
 
    	
 
    
	
Rick   E Winningham
    	
 
    	
 
    
	
 
    	
 
    	
 
    
	
Date:
    	
May 5,   2014.
    	
 
    	
 
    
				

 

4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00230-of-00352.parquet"}]]